

## 1. Details of reporting period

Name of entity:	TrivarX Limited (the Company)
ABN:	58 008 130 336
<b>Reporting period:</b>	<b>30 June 2025</b>
Previous period:	30 June 2024
Presentation Currency	Australian Dollar (\$)

## 2. Results for announcement to the market

Key information	30 June 2025	30 June 2024	Increase/ (decrease)	Amount change
	\$	\$	%	\$
Revenues from ordinary activities	1,128,979	893,309	26.38%	235,670
Total comprehensive loss attributable to members	(972,663)	(1,491,672)	(34.79%)	519,009
Net profit/(loss) for the year attributable to members	(943,231)	(1,434,616)	(34.25%)	491,385

	Amount per Security	Franked Amount per Security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Previous Corresponding Period	Nil	Nil
Record Date for Determining Entitlements	Not applicable	Not applicable

## Commentary on results:

### 3. Statement of comprehensive income

Refer to attached financial statements

### 4. Statement of Financial Position

Refer to attached financial statements

### 5. Statement of Cash Flows

Refer to attached financial statements

### 6. Statement of Retained Earnings/Changes in Equity

Refer to attached financial statements

### 7. Dividends/Distributions

No dividends declared in the current or prior year

### 8. Details of Dividend Reinvestment Plans

Not applicable

## 9. Net Tangible Assets Per Share

	30 Jun 2025	30 Jun 2024
Net tangible asset/(liability) backing per ordinary security (cents)	0.10	(0.06)

## 10. Details of entities over which control has been gained or lost during the period

### Control gained over entities

Name of entity (or group of entities)	N/A
Date control gained	N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

### Loss of control over entities

Name of entity (or group of entities)	Refer to note (i) below
Date control lost	25 March 2025
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Profit/(loss) of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

(i) BioProspect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Invatec Health Pty Ltd and Annapanna Pty Ltd.

## 11. Details of Associates and Joint Venture entities

Name of associate or joint venture entity	N/A
Reporting entity's percentage holding in this entity	N/A
Contribution to net profit/(loss) (where material)	N/A
Aggregate share of profits/(losses) of the above entity (where material)	N/A

## 12. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached financial statements
--

## 13. Foreign entities

Refer to attached financial statements
--

## 14. Commentary on results for period and explanatory information

Refer to commentary on page 6 of the attached preliminary report.
---

## 15. Audit

---

This Preliminary final report is based on accounts which are in the process of being audited. It is likely that the Auditor will issue an Independent Auditor's Report that will contain an 'Emphasis of Matter' paragraph drawing attention to a material uncertainty that may cast a significant doubt about the Group's ability to continue as a going concern. The attached Preliminary Final Report has been prepared on a going concern basis. Please refer to note 2 Going Concern.

---

Authorised for release by the Board

A handwritten signature in black ink, appearing to read "D Trimboli".

Mr David Trimboli  
**Non-Executive Chair**

29 August 2025

Statement of Profit or Loss and Other Comprehensive Income.....	2
Statement of Financial Position.....	3
Statement of Changes in Equity.....	4
Statement of Cash Flows.....	5
Notes to the financial statements.....	6

**TrivarX Limited**  
**Statement of profit or loss and other comprehensive income**  
**for the year ended 30 June 2025**



		<b>Consolidated</b>	
	<b>Note</b>	<b>2025</b>	<b>2024</b>
		<b>\$</b>	<b>\$</b>
<b>Revenue</b>			
Other income		1,128,979	893,309
<b>Expenses</b>			
Employee costs		(974,333)	(779,575)
Research and development expenses		(26,393)	(14,274)
Finance costs		(33,627)	(13,446)
Depreciation and amortisation expense		(52,467)	(93,133)
Other expenses	3	(985,390)	(1,427,497)
<b>Loss before income tax expense</b>		<b>(943,231)</b>	<b>(1,434,616)</b>
Income tax expense		-	-
<b>Loss after income tax expense for the year attributable to the Owners of TrivarX Limited</b>		<b>(943,231)</b>	<b>(1,434,616)</b>
<b>Other comprehensive income</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation		(29,432)	(57,056)
Other comprehensive (loss)/income for the year, net of tax		(29,432)	(57,056)
<b>Total comprehensive loss for the year attributable to the Owners of TrivarX Limited</b>		<b>(972,663)</b>	<b>(1,491,672)</b>
Basic earnings per share (cents)		(0.19)	(0.43)
Diluted earnings per share (cents)		(0.19)	(0.43)

*The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

TrivarX Limited  
Statement of financial position  
as at 30 June 2025



		Consolidated	
	Note	2025	2024
		\$	\$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		1,246,838	848,096
Other current assets		49,929	67,140
<b>Total current assets</b>		<u>1,296,767</u>	<u>915,236</u>
<b>Non-current assets</b>			
Other assets		7,756	7,668
Right-of-use assets		164,259	15,362
Intangibles	4	12,014,813	10,129,209
<b>Total non-current assets</b>		<u>12,186,828</u>	<u>10,152,239</u>
<b>Total assets</b>		<u><b>13,483,595</b></u>	<u><b>11,067,475</b></u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		440,006	938,044
Lease liabilities		34,649	15,990
Employee benefits		80,653	58,139
Other liabilities		141,534	161,828
<b>Total current liabilities</b>		<u><b>696,842</b></u>	<u><b>1,174,001</b></u>
<b>Non-current liabilities</b>			
Lease liabilities		134,376	-
<b>Total non-current liabilities</b>		<u><b>134,376</b></u>	<u><b>-</b></u>
<b>Total liabilities</b>		<u><b>831,218</b></u>	<u><b>1,174,001</b></u>
<b>Net assets</b>		<u><b>12,652,377</b></u>	<u><b>9,893,474</b></u>
<b>Equity</b>			
Issued capital	5	109,959,773	106,580,333
Reserves		6,604,728	6,282,034
Accumulated losses		(103,912,124)	(102,968,893)
<b>Total equity</b>		<u><b>12,652,377</b></u>	<u><b>9,893,474</b></u>

*The above statement of financial position should be read in conjunction with the accompanying notes*

**TrivarX Limited**  
**Statement of changes in equity**  
**for the year ended 30 June 2025**



<b>Consolidated</b>	<b>Issued capital \$</b>	<b>Foreign currency translation reserves \$</b>	<b>Share based payments reserves \$</b>	<b>Accumulated losses \$</b>	<b>Total equity \$</b>
<b>Balance at 1 July 2023</b>	<b>101,800,671</b>	<b>(40,953)</b>	<b>6,240,612</b>	<b>(101,655,885)</b>	<b>6,344,445</b>
Loss after income tax for the year	-	-	-	(1,434,616)	(1,434,616)
Other comprehensive loss for the year, net of tax	-	(57,056)	-	-	(57,056)
Total comprehensive loss for the year	-	(57,056)	-	(1,434,616)	(1,491,672)
<i>Transactions with Owners in their capacity as Owners:</i>					
Net contributions of equity (note 5)	5,112,719	-	-	-	5,112,719
Share-based payments	-	-	261,039	-	261,039
Share issue costs	(333,057)	-	-	-	(333,057)
Transfer from reserves	-	(121,608)	-	121,608	-
<b>Balance at 30 June 2024</b>	<b>106,580,333</b>	<b>(219,617)</b>	<b>6,501,651</b>	<b>(102,968,893)</b>	<b>9,893,474</b>

<b>Consolidated</b>	<b>Issued capital \$</b>	<b>Foreign currency translation reserves \$</b>	<b>Share based payments reserves \$</b>	<b>Accumulated losses \$</b>	<b>Total equity \$</b>
<b>Balance at 1 July 2024</b>	<b>106,580,333</b>	<b>(219,617)</b>	<b>6,501,651</b>	<b>(102,968,893)</b>	<b>9,893,474</b>
Loss after income tax for the year	-	-	-	(943,231)	(943,231)
Other comprehensive loss for the year, net of tax	-	(29,432)	-	-	(29,432)
Total comprehensive loss for the year	-	(29,432)	-	(943,231)	(972,663)
<i>Transactions with Owners in their capacity as Owners:</i>					
Net contributions of equity (note 5)	3,680,650	-	-	-	3,680,650
Share-based payments	-	-	285,494	-	285,494
Share issue costs	(301,210)	-	66,632	-	(234,578)
<b>Balance at 30 June 2025</b>	<b>109,959,773</b>	<b>(249,049)</b>	<b>6,853,777</b>	<b>(103,912,124)</b>	<b>12,652,377</b>

*The above statement of changes in equity should be read in conjunction with the accompanying notes*

**TrivarX Limited**  
**Statement of cash flows**  
**for the year ended 30 June 2025**



Note	Consolidated	
	2025	2024
	\$	\$
<b>Cash flows from operating activities</b>		
R&D grant received	1,031,073	888,829
Payments to suppliers and employees	(1,258,156)	(2,446,894)
Interest received	8,722	4,880
Other (GST refund)	56,707	77,752
Net cash used in operating activities	(161,654)	(1,475,433)
<b>Cash flows from investing activities</b>		
Payments for intangibles	(2,091,333)	(2,500,432)
Net cash used in investing activities	(2,091,333)	(2,500,432)
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares	2,734,321	4,702,267
Proceeds from borrowings	500,000	55,000
Repayment of borrowings	(500,000)	(55,000)
Transaction costs related to loans and borrowings	(28,088)	-
Payment of lease liabilities	(55,108)	(94,577)
Net cash provided by financing activities	2,651,125	4,607,690
Net increase in cash and cash equivalents	398,138	631,825
Cash and cash equivalents at the beginning of the financial year	848,096	214,113
Effects of exchange rate changes on cash and cash equivalents	604	2,158
<b>Cash and cash equivalents at the end of the financial year</b>	<b>1,246,838</b>	<b>848,096</b>

*The above statement of cash flows should be read in conjunction with the accompanying notes*



**Note 1. General information**

TrivarX Limited ('TrivarX', 'the Company', or 'the Parent') is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.

**Note 2. Basis of preparation**

The preliminary final report has been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. The preliminary final report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

This preliminary final report has been prepared in accordance with ASX Listing Rules as they relate to the Appendix 4E and in accordance with the recognition and measurement requirements of the Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the Corporations Act 2001. As such, this preliminary final report does not include all the notes of the type included in an annual financial report and accordingly, should be read in conjunction with the annual report for the year ended 30 June 2024 and any ASX announcements made by the Company during the period.

**Going concern**

The preliminary final report has been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business. The Group incurred a loss for the year ended 30 June 2025 of \$943,231 (2024: \$1,434,616) and net cash outflows from operations was \$161,654 (2024: \$1,475,433). As at 30 June 2025, cash and cash equivalents was \$1,246,838 (2024: \$848,096).

Whilst the Group is expected to be cash-flow negative in the foreseeable future because of research and development activities, the ability of the Group to continue as a going concern is dependent on securing additional funding through equity or debt or a combination of both to continue to fund its operational and technological development activities. These conditions indicate a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

The directors believe the Group will continue as a going concern after consideration of the following factors:

- the Group successfully raised \$3,680,650 (before transaction costs) during the financial year ended 30 June 2025 and management has confidence in its ability to raise further capital when required.
- the Group anticipates the receipt, subject to approval, of government grants and tax incentives related to its research and development activities.
- the directors of TrivarX Limited have reason to believe that in addition to the cash flow currently available, the level of expenditure can be managed to meet working capital requirements for at least the next twelve (12) months.

The preliminary final report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or liabilities that might be necessary should the Group not continue as a going concern and meet its debts as and when they become due and payable.

The directors plan to continue the Group's operations on the basis outlined above and believe there will be sufficient funds for the Group to meet its obligations and liabilities for at least twelve (12) months from the date of this report.

**Note 3. Other expenses**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Consulting and advisory expenses	529,790	820,758
Business development and travel related costs	-	8,841
Insurance	72,530	97,046
Listing fees and share registry charges	95,549	105,162
Legal fees	56,382	58,257
Sales and marketing	-	51,775
Other administration expenses	231,139	285,658
	<u>985,390</u>	<u>1,427,497</u>

**Note 4. Non-current assets - intangibles**

	<b>Consolidated</b>	
	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Development – at cost	4,247,051	4,247,051
Capitalised costs	679,867	690,818
Less: impairment	(2,241,972)	(2,241,972)
	<b>2,684,946</b>	<b>2,695,897</b>
MEB-001 application development – at cost	8,698,333	7,433,312
EurAsia development – at cost	446,072	-
MLB Proof of Concept development – at cost	185,462	-
	<b>9,329,867</b>	<b>7,433,312</b>
	<b>12,014,813</b>	<b>10,129,209</b>

*Accounting policy for intangible assets*

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

*Research and development*

Research costs are expensed in the period in which they are incurred. Development costs are capitalised when it is probable that the project will be a success considering its commercial and technical feasibility; the Group is able to use or sell the asset; the Group has sufficient resources and intent to complete the development; and its costs can be measured reliably. Capitalised development costs are amortised on a straight-line basis over the period of their expected benefit, being their finite life of 5 years.

The recoverable amount of the group's indefinite life intangible assets has been determined by fair value less costs to sell based on the cost approach, with the recoverable amount based on the cost to collect further data files from recent and ongoing studies. Consideration has also been given to outcomes of the studies and progress in developing the technology as well as published costs of studies. Key assumptions include the costs paid to suppliers for data files as well as the allocation of internal staff time to generate and analyse additional data files. There has been no change since the prior period in the calculation method.

**Note 5. Equity - issued capital**

	2025 Shares	Consolidated 2024 Shares	2025 \$	2024 \$
Fully paid ordinary shares	<u>619,826,341</u>	<u>409,649,428</u>	<u>109,959,773</u>	<u>106,580,333</u>
<i>Movements in ordinary share capital</i>				

Details	Date	Shares	Issue price	\$
<b>Balance</b>	<b>30 June 2023</b>	<b>4,547,927,099</b>		<b>101,800,671</b>
Issue of shares	5 July 2023	602,666,664	\$0.0015	904,000
Placement	16 August 2023	950,150,000	\$0.0015	1,425,225
Issue of shares	13 October 2023	613,634,259	\$0.0015	920,451
Consolidation 20:1		(6,378,658,479)		
Issue of shares	14 November 2023	100,000	\$0.0300	3,000
Issue of shares	17 November 2023	1,211,507	\$0.0300	36,345
Issue of shares	18 December 2023	1,047,633	\$0.0300	31,429
Issue of shares	14 February 2024	200,000	\$0.0300	6,000
Issue of shares	29 February 2024	100,000	\$0.0300	3,000
Issue of shares	25 March 2024	100,000	\$0.0300	3,000
Placement	10 May 2024	70,970,745	\$0.0250	1,774,269
Issue of shares	10 May 2024	200,000	\$0.0300	6,000
Share issue costs		-		(333,057)
<b>Balance</b>	<b>30 June 2024</b>	<b>409,649,428</b>		<b>106,580,333</b>
Issue of shares	10 July 2024	3,960,000	\$0.0250	99,000
Issue of shares	10 July 2024	14,000,000	\$0.0250	350,000
Placement	10 July 2024	29,029,255	\$0.0250	725,731
Issue of shares	10 July 2024	400,000	\$0.0300	12,000
Issue of shares	4 December 2024	7,831,756	\$0.0220	172,299
Issue of shares	14 January 2025	1,627,653	\$0.0160	26,042
Placement	24 March 2025	56,401,855	\$0.0150	846,028
Placement	24 March 2025	46,417,043	\$0.0150	696,256
Issue of shares	25 March 2025	422,743	\$0.0190	8,032
Issue of shares	25 March 2025	473,314	\$0.0170	8,046
Placement	20 May 2025	47,181,102	\$0.0150	707,717
Issue of shares	10 June 2025	843,213	\$0.0130	10,962
Issue of shares	10 June 2025	1,412,509	\$0.0110	15,537
Issue of shares	10 June 2025	176,470	\$0.0170	3,000
Share issue costs		-		(301,210)
<b>Balance</b>	<b>30 June 2025</b>	<b>619,826,341</b>		<b>109,959,773</b>

**Ordinary shares**

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

**Share buy-back**

There is no current on-market share buy-back.

**Note 5. Equity - issued capital (continued)**

*Capital Management*

Due to the nature of the Group's activities, the Group does not have ready access to credit facilities, with the primary source of funding being equity and/or debt raisings. Therefore, the focus of the Group's capital risk management is the current working capital position against the requirements of the Group to meet research and development programs and corporate overheads. The Group's strategy is to ensure appropriate liquidity is maintained to meet anticipated operating requirements, with a view to initiating appropriate capital raisings as required. Any surplus funds are invested with major financial institutions.

*Accounting policy for issued capital*

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.